AG真人官方

Dyadic International (DYAI) is raising $5.75 million gross through a firmly-underwritten public offering of 6,052,000 common shares at $0.95, a 19% discount to the 29-Jul-25 close ($1.175). Net proceeds are estimated at $5.35 million after $0.40 million underwriting fees/expenses and will be used for working capital, product development, and sales & marketing; management retains full discretion over deployment.

The deal enlarges the share count 20% to 36.1 million and lifts pro-forma tangible book value from $0.03 to $0.17 per share, but new investors face immediate $0.78 dilution. Craig-Hallum receives 302,600 five-year warrants at $1.0925.

Nasdaq compliance remains a critical overhang. DYAI received notices in Jun-25 (market-value < $35 m) and Jul-25 (bid-price < $1) and has until 20-Dec-25 and 13-Jan-26, respectively, to cure or face potential delisting. The raise modestly improves market-cap but does not itself resolve either metric.

President/COO Joseph Hazelton signals insider support by buying 26,000 shares in the offering. Post-offering float remains under $75 m, allowing the company to keep using the S-3 鈥渂aby shelf.鈥�

No changes to strategy were disclosed; Dyadic continues to commercialize its C1 and Dapibus鈩� microbial protein platforms across life-sciences, food, and bio-industrial markets while pursuing funded pharma collaborations.

Dyadic International (Nasdaq: DYAI) filed a Form 8-K on 23 Jul 2025 under Item 7.01 (Reg FD) to furnish an investor presentation titled 鈥淧recision engineered recombinant protein production that redefines performance, scalability and economy.鈥� The deck, posted on the company鈥檚 website and attached as Exhibit 99.1, outlines a strategic shift from research-driven to commercially focused operations. Management plans to monetize its patented C1 and Dapibus鈩� gene-expression platforms by supplying high-value, non-therapeutic proteins to the life-science, food, nutrition and industrial bioprocessing markets. No new financial results, guidance, or transactional details were disclosed. Because the material is 鈥渇urnished鈥� rather than 鈥渇iled,鈥� it is not subject to Section 18 liability and will not be automatically incorporated into future Securities Act or Exchange Act filings. Exhibit 104 contains the inline XBRL cover page data.

Dyadic International, Inc. (Nasdaq: DYAI) received a Nasdaq Listing Qualifications notice on 17-Jul-2025 after its common stock failed to meet the $1.00 minimum bid price for the past 30 consecutive business days, violating Rule 5550(a)(2).

The notice does not immediately affect DYAI鈥檚 listing. The company has 180 calendar days鈥攗ntil 13-Jan-2026鈥攖o regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive trading days. If the requirement is unmet, Dyadic may qualify for a second 180-day grace period, provided it satisfies all initial listing standards other than bid price and formally notifies Nasdaq of its remediation plan. Failure to cure could result in delisting, with the option to appeal.

Management 鈥渋ntends to actively monitor鈥� share price and explore alternatives to resolve the deficiency. The filing also reminds investors that the company remains out of compliance with the $35 million Market Value of Listed Securities rule (Rule 5550(b)(2)); that separate deficiency must be remedied by 20-Dec-2025. Either unresolved deficiency can independently trigger delisting.

Dyadic International, Inc. (Nasdaq: DYAI) filed a Form 8-K on 2 July 2025 to disclose a branding update. In 30 days the company will begin operating under the business name 鈥淒yadic Applied BioSolutions.鈥� The filing clarifies that the legal corporate name remains 鈥淒yadic International, Inc.,鈥� the DYAI ticker is unchanged, and the company will continue to trade on the Nasdaq Stock Market. The disclosure is provided under Item 7.01 (Regulation FD) and is furnished鈥攏ot filed鈥攖hereby carrying no Section 18 liability and no direct impact on financial statements. No financial data, operational revisions, or strategic transactions are included; the report solely communicates the forthcoming DBA designation and furnishes the related press release as Exhibit 99.1.

Dyadic International (NASDAQ:DYAI) filed an 8-K disclosing receipt of a Nasdaq Listing Rule 5550(b)(2) deficiency notice for failing to maintain the minimum $35 million Market Value of Listed Securities (MVLS).

The stock has been below the threshold for 30 consecutive business days, activating a 180-day cure period ending December 20, 2025. To regain compliance, DYAI鈥檚 MVLS must close at or above $35 million for at least 10 consecutive trading days before the deadline. Failure would prompt a delisting determination, which the company could appeal, though success is not assured.

The notice has no immediate effect on Nasdaq trading but flags heightened liquidity and financing risk. Management says it will monitor MVLS and 鈥渆valuate available options,鈥� yet outlines no specific actions. Forward-looking statements reiterate ongoing losses, capital needs, and potential breaches of other listing standards, underscoring uncertainty for shareholders.

Dyadic International, Inc. (NASDAQ: DYAI) filed an 8-K to disclose the final results of its 20 June 2025 Annual Meeting of Shareholders.

• Director election 鈥� Class III: Founder & CEO Mark A. Emalfarb was re-elected to serve until the 2028 meeting with 15,946,385 votes FOR (96.0% of votes cast) versus 421,896 WITHHELD and 7,892,709 broker non-votes.
• Auditor ratification: Crowe LLP was confirmed as independent registered public accounting firm for FY-2025 with an overwhelming 24,013,307 FOR (99.0%), 237,523 AGAINST and 10,160 ABSTAIN.
• Say-on-pay (advisory): Compensation of named executive officers received 15,765,072 FOR (95.9%), 522,744 AGAINST, 80,465 ABSTAIN, and 7,892,709 broker non-votes.
• Say-on-pay frequency: Shareholders strongly preferred an annual advisory vote: 15,443,558 votes for 1-year, handily exceeding 716,692 (2-years) and 13,576 (3-years). Abstentions were 194,455.

Based on these results, the Board and its Compensation Committee have resolved that future advisory votes on executive compensation will be held once every year.

No other matters were brought before the meeting, and there were no disclosures of earnings, major transactions or material events beyond the voting outcomes.

Dyadic International, Inc. (DYAI) 鈥� Form 4 insider filing details the June 20, 2025 vesting and conversion of 10,776 restricted stock units (RSUs) held by outgoing director Michael P. Tarnok.

The RSUs automatically vested "upon retirement from service as a member of the board of directors," and were converted into an equal number of DYAI common shares. Transaction code M denotes an exempt, non-open-market conversion; no shares were sold and no cash price was paid (exercise price reported as $0).

Following the transaction Mr. Tarnok鈥檚 direct beneficial ownership rises to 281,033 common shares, reinforcing post-retirement equity alignment. The filing, signed June 24, 2025, indicates the action was performed by an attorney-in-fact on the insider鈥檚 behalf. No 10b5-1 trading plan box is checked, and there are no derivative instruments remaining.

For investors, the disclosure is largely administrative. The conversion results in a modest 0.04 % increase to Dyadic鈥檚 basic share count (based on ~26 M shares outstanding as of the last 10-K) and signals a board transition already in progress. No information on replacement directors, strategic impact, or cash compensation is provided in this filing.